NASDAQ:XBIT

XBiotech - XBIT Stock Forecast, Price & News

$5.09

-0.05 (-0.97%)

(As of 08/15/2022 12:00 AM ET)

Add

Compare

Today's Range: $5.00
▼
$5.25
50-Day Range: $5.06
▼
$6.26
52-Week Range: $4.87
▼
$16.50

Volume: 84,721 shs
Average Volume: 91,489 shs
Market Capitalization: $154.93 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

About XBiotech (NASDAQ:XBIT) Stock

XBiotech Inc., a biopharmaceutical company, discovers, develops, and commercializes True Human monoclonal antibodies for treating various diseases. The company focuses on developing a pipeline of product candidates targeting both inflammatory and infectious diseases. It is also developing interleukin-1 alpha therapies to treat variety of medical conditions, such as cancer, stroke, heart attack, or arthritis; and mediates tissue breakdown, angiogenesis, the formation of blood clots, malaise, muscle wasting, and inflammation, and True Human COVID-19 therapy for treating the COVID-19 mutant virus. The company was incorporated in 2005 and is headquartered in Austin, Texas.

XBiotech Stock Up 1.2 %

Shares of XBiotech stock opened at $5.14 on Monday. The business's fifty day simple moving average is $5.47 and its 200-day simple moving average is $7.35. XBiotech has a 52 week low of $4.87 and a 52 week high of $16.50.

Receive XBIT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for XBiotech and its competitors with MarketBeat's FREE daily newsletter.

XBIT Stock News Headlines

August 14, 2022 | finance.yahoo.com

We Think XBiotech (NASDAQ:XBIT) Can Afford To Drive Business Growth - Yahoo Finance

August 3, 2022 | americanbankingnews.com

Short Interest in XBiotech Inc. (NASDAQ:XBIT) Drops By 21.0%

June 21, 2022 | benzinga.com

The Daily Biotech Pulse: Thumbs Down For Acadia's Pimavanserin, Pfizer Buys Stake In Valneva, AstraZeneca - Benzinga

June 20, 2022 | globenewswire.com

XBiotech Announces Successful Completion of Phase I portion of Pancreatic Cancer Study - GlobeNewswire

May 10, 2022 | streetinsider.com

Form 10-Q XBiotech Inc. For: Mar 31 - StreetInsider.com

May 7, 2022 | benzinga.com

XBiotech Sponsored Study Titled 'Natrunix or Placebo in Combination With Methotrexate in Rheumatoid Arthr - Benzinga

May 6, 2022 | benzinga.com

XBiotech Sponsored Study Titled 'Natrunix Versus Methotrexate in Rheumatoid Arthritis' Posted To Clinical - Benzinga

April 29, 2022 | uk.investing.com

74 Biggest Movers From Yesterday By Benzinga - Investing.com UK

April 29, 2022 | benzinga.com

Why Are XBiotech Shares Trading Higher Today - Benzinga - Benzinga

April 28, 2022 | globenewswire.com

XBiotech Announces French National Agency (ANSM) Approval and National Cancer Institute (INSA) funding to Support Phase I/II/III Clinical Study for Natrunix™ in Combination with Trifluridine/Tipiracil (TASKIN) for Treatment of Metastatic Colorectal Cancer - GlobeNewswire

April 19, 2022 | fool.com

Johnson & Johnson (JNJ) Q1 2022 Earnings Call Transcript - The Motley Fool

March 15, 2022 | finance.yahoo.com

XBiotech (NASDAQ:XBIT) shareholders have endured a 48% loss from investing in the stock a year ago

February 3, 2022 | nasdaq.com

White House mobilizes 'war room' to boost Fed nominees as attacks pile up - Nasdaq

February 2, 2022 | seekingalpha.com

J&J to record $610M impairment charge from terminating development of therapy - Seeking Alpha

February 2, 2022 | globenewswire.com

XBiotech Inks Clinical Manufacturing Deal - GlobeNewswire

January 27, 2022 | finance.yahoo.com

XBiotech Announces First Patient Enrolled in Phase I Clinical Trial for Novel Arthritis Therapy Natrunix-SQ - Yahoo Finance

January 27, 2022 | finance.yahoo.com

The Natural and Organic Personal Care Product Market to Record 5.90% Y-O-Y Growth Rate in 2021 | L'Oréal SA - The company, in collaboration with Albéa Services SAS, launched a paper-based cosmetic tube in November 2019 | Technavio - Yahoo Finance

January 26, 2022 | globenewswire.com

XBiotech Announces First Patient Enrolled in Phase I Clinical Trial for Novel Arthritis Therapy Natrunix-SQ - GlobeNewswire

January 26, 2022 | finance.yahoo.com

XBiotech Announces First Patient Enrolled in Phase I Clinical Trial for Novel Arthritis Therapy Natrunix-SQ

December 28, 2021 | seekingalpha.com

FDA updates EUA for COVID convalescent plasma limiting use to certain patients - Seeking Alpha

December 15, 2021 | finance.yahoo.com

CyanConnode Holdings' (LON:CYAN) investors will be pleased with their massive 383% return over the last year - Yahoo Finance

December 15, 2021 | finance.yahoo.com

Do Insiders Own Lots Of Shares In XBiotech Inc. (NASDAQ:XBIT)?

December 13, 2021 | benzinga.com

XBiotech Announces FDA's Division Of Rheumatology Has Authorized Co. To Commence Clinical Development Of Natrunix - Benzinga

December 13, 2021 | globenewswire.com

FDA Approves XBiotech's IND in Rheumatology - GlobeNewswire

December 13, 2021 | finance.yahoo.com

FDA Approves XBiotech’s IND in Rheumatology

See More Headlines

30 days | 90 days | 365 days | Advanced Chart

Receive XBIT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for XBiotech and its competitors with MarketBeat's FREE daily newsletter.

XBIT Company Calendar

Today: 8/15/2022
Next Earnings (Estimated): 8/15/2022
Fiscal Year End: 12/31/2022

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:XBIT
CUSIP: N/A
CIK: 1626878
Web: www.xbiotech.com
Phone: (512) 386-2900
Fax: 512-386-5505
Employees: 97
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): N/A
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-17,410,000.00
Net Margins: -242.26%
Pretax Margin: -302.54%
Return on Equity: -10.05%
Return on Assets: -9.81%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 28.99
Quick Ratio: 28.99

Sales & Book Value

Annual Sales: $18.39 million
Price / Sales: 8.42
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $8.86 per share
Price / Book: 0.57

Miscellaneous

Outstanding Shares: 30,439,000
Free Float: 21,977,000
Market Cap: $154.93 million
Optionable: Optionable
Beta: 1.24

Key Executives

Mr. John Simard (Age 60)
Founder, Pres, CEO & Chairman
Comp: $7.79M
Ms. Queena Han B.A. (Age 55)
C.G.A., CPA, CPA, VP of Fin. & HR and Sec.
Comp: $489.89k
Dr. Sushma Shivaswamy Ph.D. (Age 44)
Chief Scientific Officer
Comp: $568.74k
Mr. Benjamín Guzmán (Age 66)
Sr. VP of Corp. Strategy & Fin.
Ms. Lisa Simard
Director of Corp. Strategy - XBiotech USA, Inc.

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

XBIT Stock - Frequently Asked Questions

How have XBIT shares performed in 2022?: XBiotech's stock was trading at $11.13 at the beginning of 2022. Since then, XBIT stock has decreased by 54.2% and is now trading at $5.10.
View the best growth stocks for 2022 here.
When is XBiotech's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Monday, August 15th 2022.
View our XBIT earnings forecast.
What is John Simard's approval rating as XBiotech's CEO?: 20 employees have rated XBiotech Chief Executive Officer John Simard on Glassdoor.com. John Simard has an approval rating of 58% among the company's employees. This puts John Simard in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.
What other stocks do shareholders of XBiotech own?: Based on aggregate information from My MarketBeat watchlists, some companies that other XBiotech investors own include Micron Technology (MU), Gilead Sciences (GILD), Advanced Micro Devices (AMD), Walt Disney (DIS), Cisco Systems (CSCO), NVIDIA (NVDA), Inovio Pharmaceuticals (INO), Intel (INTC), Pfizer (PFE) and Block (SQ).

When did XBiotech IPO?: (XBIT) raised $76 million in an initial public offering on Wednesday, April 15th 2015. The company issued 4,000,000 shares at $18.00-$20.00 per share. WR Hambrecht + Co served as the underwriter for the IPO.
What is XBiotech's stock symbol?: XBiotech trades on the NASDAQ under the ticker symbol "XBIT."
Who are XBiotech's major shareholders?: XBiotech's stock is owned by a number of retail and institutional investors. Top institutional shareholders include Credit Suisse AG (0.74%), Renaissance Technologies LLC (0.26%), Connor Clark & Lunn Investment Management Ltd. (0.16%), Northern Trust Corp (0.14%), Trexquant Investment LP (0.10%) and BNP Paribas Arbitrage SA (0.03%). Insiders that own company stock include John Simard, Queena Han, Street Financial SA Bay, Sushma Shivaswamy and W Thorpe Mckenzie.
View institutional ownership trends.
How do I buy shares of XBiotech?: Shares of XBIT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is XBiotech's stock price today?: One share of XBIT stock can currently be purchased for approximately $5.10.
How much money does XBiotech make?: XBiotech (NASDAQ:XBIT) has a market capitalization of $155.24 million and generates $18.39 million in revenue each year.
How can I contact XBiotech?: XBiotech's mailing address is 5217 Winnebago Ln, AUSTIN TX, 78744. The official website for the company is www.xbiotech.com. The biopharmaceutical company can be reached via phone at (512) 386-2900, via email at swhitehurst@xbiotech.com, or via fax at 512-386-5505.

This page (NASDAQ:XBIT) was last updated on 8/15/2022 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here